Bristol-Myers Squibb, CHECKMATE-76K, FDA, melanoma, Opdivo
Nivolumab is approved by the FDA for adjuvant treatment of Stage IIB/C melanoma
Nov 2023: Nivolumab (Opdivo, Bristol-Myers Squibb Company) was granted approval by the Food and Drug Administration as an adjuvant therapy for Stage IIB/C melanoma in patients 12 years of age and older who had undergone complete..
BMS, Bristol Myers Squibb, Immunotherapy, metastatic melanoma, nivolumab and relatlimab, nivolumab and relatlimab-rmbw, Opdualag, USFDA
First LAG-3-Blocking antibody combination, Opdualag™ (nivolumab and relatlimab-rmbw), is approved by FDA for patients with unresectable or metastatic melanoma
April 2022: The US Food and Drug Administration (FDA) has approved Opdualag (nivolumab and relatlimab-rmbw), a new, first-in-class fixed-dose combination of nivolumab and relatlimab administered as a single intravenous infusion, f..
Immunocore Limited, Kimmtrak, metastatic uveal melanoma, tebentafusp-tebn, uveal melanoma
Tebentafusp-tebn is approved for unresectable or metastatic uveal melanoma
March 2022: Tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, has been licenced by the Food and Drug Administration for HLA-A*02:01-positive adult patients with unresectab..
CD-38, FDA, HORIZON, immunomodulatory agent, melphalan flufenamide, multiple myeloma, NCT02963493, Oncopeptides AB, Pepaxto
Melphalan flufenamide receives approval from the FDA for relapsed or refractory multiple myeloma
August 2021: Melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with dexamethasone has been granted accelerated approval by the Food and Drug Administration for adult patients with relapsed or refractory multiple myel..
KEYTRUDA, Merck, NCT02362594, Pembrolizumab, RECIST, USFDA
Pembrolizumab is approved by FDA for adjuvant treatment of melanoma
On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after full resection. The approval ..
Bariatric surgery, Delhi, India, USA
Bariatric surgery can reduce the risk of melanoma
In addition to rapid and lasting weight loss and other health benefits, bariatric surgery is now associated with a 61% reduced risk of malignant melanoma, which is the deadliest skin cancer most closely associated with excessive s..